What is the share price of Sanjivani Paranteral Ltd (SANJIVIN) today?
The share price of SANJIVIN as on 5th December 2025 is ₹205.45. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanjivani Paranteral Ltd (SANJIVIN) share?
The past returns of Sanjivani Paranteral Ltd (SANJIVIN) share are- Past 1 week: 17.51%
- Past 1 month: 2.07%
- Past 3 months: -17.04%
- Past 6 months: -16.69%
- Past 1 year: -32.13%
- Past 3 years: 407.91%
- Past 5 years: 1920.16%
What are the peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN)?
The peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN) include:What is the market cap of Sanjivani Paranteral Ltd (SANJIVIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd (SANJIVIN) is ₹252.38 Cr as of 5th December 2025.What is the 52 week high and low of Sanjivani Paranteral Ltd (SANJIVIN) share?
The 52-week high of Sanjivani Paranteral Ltd (SANJIVIN) is ₹396.95 and the 52-week low is ₹170.What is the PE and PB ratio of Sanjivani Paranteral Ltd (SANJIVIN) stock?
The P/E (price-to-earnings) ratio of Sanjivani Paranteral Ltd (SANJIVIN) is 31.12. The P/B (price-to-book) ratio is 6.33.Which sector does Sanjivani Paranteral Ltd (SANJIVIN) belong to?
Sanjivani Paranteral Ltd (SANJIVIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanjivani Paranteral Ltd (SANJIVIN) shares?
You can directly buy Sanjivani Paranteral Ltd (SANJIVIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanjivani Paranteral Ltd
SANJIVIN Share Price
205.456.19% (-13.55)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANJIVIN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANJIVIN Performance & Key Metrics
SANJIVIN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.74 | 6.33 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
SANJIVIN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SANJIVIN Company Profile
Sanjivani Paranteral is engaged in the business of pharmaceutical products.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
SANJIVIN Sentiment Analysis
SANJIVIN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANJIVIN Stock Summary · November 2025
The company is poised for growth despite facing operational challenges and regulatory scrutiny, particularly in the Latin American market. A strong demand for generic pharmaceuticals, driven by loss of exclusivity and global healthcare policies, underpins its optimistic revenue outlook, with expectations of at least 10% year-over-year growth by FY '26. Strategic diversification into new markets, including the GCC and CIS regions, alongside a focus on enhancing operational efficiency through modernization and AI, positions the company favorably. While recent disruptions have impacted revenue, a robust order book and successful regulatory approvals for new ventures signal potential recovery. Effective cost management and a commitment to shareholder relations further bolster confidence in navigating market complexities.
SANJIVIN Stock Growth Drivers
SANJIVIN Stock Growth Drivers
6Regulatory Approvals and Operational Milestones
The company has successfully secured all regulatory approvals for its SPL Infusion venture, with commercial
Strong Demand and Market Position
The company is positioned favorably within the pharmaceutical sector, with a strong demand outlook for
SANJIVIN Stock Challenges
SANJIVIN Stock Challenges
4Revenue Decline and Financial Performance
In Q2 FY '26, the company reported a revenue decline of 14.5% year-on-year, amounting to
Export Challenges and Regulatory Scrutiny
The company faced significant challenges in its export operations, particularly in Latin America, where increased
SANJIVIN Forecast
SANJIVIN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SANJIVIN
SANJIVIN
Income
Balance Sheet
Cash Flow
Annual Normal View
SANJIVIN Income Statement
SANJIVIN Income Statement
Annual Normal View
| Financial Year | FY 2024 | FY 2025 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 54.93 | 71.32 | 69.86 | |||
Raw Materials | 34.37 | 33.56 | 58.86 | |||
| Power & Fuel Cost | 1.14 | 1.37 | ||||
| Employee Cost | 3.74 | 4.99 | ||||
| Selling & Administrative Expenses | 9.49 | 9.83 | ||||
| Operating & Other expenses | -2.57 | 9.99 | ||||
EBITDA | 8.76 | 11.58 | 11.00 | |||
| Depreciation/Amortization | 0.93 | 0.62 | 0.67 | |||
| PBIT | 7.83 | 10.96 | 10.33 | |||
| Interest & Other Items | 0.25 | 0.59 | 0.66 | |||
| PBT | 7.58 | 10.37 | 9.67 | |||
| Taxes & Other Items | 1.41 | 2.26 | 2.19 | |||
| Net Income | 6.17 | 8.11 | 7.48 | |||
| EPS | 5.28 | 6.88 | 6.30 | |||
| DPS | 0.00 | 0.00 | 0.50 | |||
| Payout ratio | 0.00 | 0.00 | 0.08 |
SANJIVIN Company Updates
SANJIVIN Stock Peers
SANJIVIN Past Performance & Peer Comparison
SANJIVIN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanjivani Paranteral Ltd | 31.12 | 6.33 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
SANJIVIN Stock Price Comparison
Compare SANJIVIN with any stock or ETFCompare SANJIVIN with any stock or ETF
SANJIVIN
SANJIVIN Holdings
SANJIVIN Shareholdings
SANJIVIN Promoter Holdings Trend
SANJIVIN Promoter Holdings Trend
SANJIVIN Institutional Holdings Trend
SANJIVIN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding History
SANJIVIN Shareholding History
Foreign Institutions
smallcases containing SANJIVIN stock
smallcases containing SANJIVIN stock
Looks like this stock is not in any smallcase yet.
SANJIVIN Events
SANJIVIN Events
SANJIVIN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANJIVIN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANJIVIN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANJIVIN has not given any dividends in last 5 years
SANJIVIN Upcoming Dividends
SANJIVIN Upcoming Dividends
No upcoming dividends are available
SANJIVIN Past Dividends
SANJIVIN Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2025
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2025
SANJIVIN Stock News & Opinions
SANJIVIN Stock News & Opinions
Articles & Videos
Earnings
Sanjivani Paranteral consolidated net profit declines 28.70% in the September 2025 quarter
Net profit of Sanjivani Paranteral declined 28.70% to Rs 1.64 crore in the quarter ended September 2025 as against Rs 2.30 crore during the previous quarter ended September 2024. Sales declined 14.51% to Rs 15.50 crore in the quarter ended September 2025 as against Rs 18.13 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales15.5018.13 -15 OPM %14.5215.72 - PBDT2.363.06 -23 PBT2.192.92 -25 NP1.642.30 -29 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Sanjivani Paranteral announces board meeting date
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Sanjivani Paranteral schedules AGM
Sanjivani Paranteral announced that the 31th Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Sanjivani Paranteral consolidated net profit rises 1.17% in the June 2025 quarter
Net profit of Sanjivani Paranteral rose 1.17% to Rs 1.73 crore in the quarter ended June 2025 as against Rs 1.71 crore during the previous quarter ended June 2024. Sales rose 8.82% to Rs 17.89 crore in the quarter ended June 2025 as against Rs 16.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales17.8916.44 9 OPM %14.7614.17 - PBDT2.462.41 2 PBT2.302.27 1 NP1.731.71 1 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Sanjivani Paranteral to declare Quarterly Results
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Sanjivani Paranteral consolidated net profit rises 73.81% in the March 2025 quarter
Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as against Rs 1.26 crore during the previous quarter ended March 2024. Sales rose 41.37% to Rs 18.18 crore in the quarter ended March 2025 as against Rs 12.86 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.12% to Rs 8.09 crore in the year ended March 2025 as against Rs 6.17 crore during the previous year ended March 2024. Sales rose 28.84% to Rs 70.10 crore in the year ended March 2025 as against Rs 54.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales18.1812.86 41 70.1054.41 29 OPM %14.3616.80 -14.7615.14 - PBDT2.842.12 34 10.978.50 29 PBT2.651.88 41 10.357.57 37 NP2.191.26 74 8.096.17 31 Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 73.81% in the March 2025 quarter
Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as against Rs 1.26 crore during the previous quarter ended March 2024. Sales rose 41.37% to Rs 18.18 crore in the quarter ended March 2025 as against Rs 12.86 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.28% to Rs 8.10 crore in the year ended March 2025 as against Rs 6.17 crore during the previous year ended March 2024. Sales rose 28.84% to Rs 70.10 crore in the year ended March 2025 as against Rs 54.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales18.1812.86 41 70.1054.41 29 OPM %14.3016.87 -14.7815.14 - PBDT2.832.13 33 10.988.51 29 PBT2.651.89 40 10.367.58 37 NP2.191.26 74 8.106.17 31 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Board of Sanjivani Paranteral recommends final dividend
Sanjivani Paranteral announced that the Board of Directors of the Company at its meeting held on 27 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 5%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Sanjivani Paranteral to discuss results
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 15.15% in the December 2024 quarter
Net profit of Sanjivani Paranteral rose 15.15% to Rs 1.90 crore in the quarter ended December 2024 as against Rs 1.65 crore during the previous quarter ended December 2023. Sales rose 15.98% to Rs 17.35 crore in the quarter ended December 2024 as against Rs 14.96 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales17.3514.96 16 OPM %14.7013.17 - PBDT2.672.14 25 PBT2.511.90 32 NP1.901.65 15 Powered by Capital Market - Live
9 months agoCapital Market - Live
In last 6 months, promoter holding in the company has increased by 2.33%
Pledged promoter holdings is insignificant